The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Tscan Therapeutics Inc shares valued at $71,974 were purchased by Lynx1 Capital Management LP on Dec 19 ’25. At $0.90 per share, Lynx1 Capital Management LP acquired 80,069 shares. The insider’s holdings grew to 7,937,416 shares worth approximately $8.25 million following the completion of this transaction.
Also, Lynx1 Capital Management LP purchased 75,500 shares, netting a total of over 67,950 in proceeds. Following the buying of shares at $0.90 each, the insider now holds 8,012,916 shares.
Before that, Lynx1 Capital Management LP had added 6,232 shares to its account. In a trade valued at $5,602, the 10% Owner bought Tscan Therapeutics Inc shares for $0.90 each. Upon closing the transaction, the insider’s holdings increased to 6,232 shares, worth approximately $8.34 million.
As published in a research note from Morgan Stanley on November 14, 2025, Tscan Therapeutics Inc [TCRX] has been rated down from an Overweight to an Equal-weight. Analysts at BTIG Research started covering the stock with ‘”a Buy”‘ outlook in a report released in mid May. As of May 13, 2024, Needham has initiated its “Buy” rating for TCRX. Earlier on June 22, 2023, Wedbush initiated its rating. Their recommendation was “an Outperform” for TCRX stock.
Analyzing TCRX Stock Performance
On last trading session, Tscan Therapeutics Inc [NASDAQ: TCRX] rose 14.20% to $1.04. The stock’s lowest price that day was $0.96, but it reached a high of $1.07 in the same session. During the last five days, there has been a surge of approximately 12.00%. Over the course of the year, Tscan Therapeutics Inc shares have dropped approximately -64.98%. Shares of the company reached a 52-week high of $3.2100 on 01/03/25 and a 52-week low of $0.8824 on 12/19/25.
Support And Resistance Levels for Tscan Therapeutics Inc (TCRX)
According to the 24-hour chart, there is a support level at 0.9767, which, if violated, would cause prices to drop to 0.9133. In the upper region, resistance lies at 1.0867. The next price resistance is at 1.1333. RSI (Relative Strength Index) is 47.91 on the 14-day chart, showing neutral technical sentiment.
Is Tscan Therapeutics Inc subject to short interest?
Stocks of Tscan Therapeutics Inc saw a sharp rise in short interest on 2025-12-15 jumping by 0.59 million shares to 2.54 million. Data from Yahoo Finance shows that the short interest on 2025-11-14 was 1.95 million shares. A jump of 23.23% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 3.11 of the overall float, the days-to-cover ratio (short ratio) jumped to 3.11.
Which companies own the most shares of Tscan Therapeutics Inc (TCRX)?
In terms of Tscan Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 7.5 in the next 12 months, up nearly 724.18% from the previous closing price of $0.91. Analysts anticipate Tscan Therapeutics Inc stock to reach 12 by 2025, with the lowest price target being 3. In spite of this, 2 analysts ranked Tscan Therapeutics Inc stock as Buy at the end of 2025.
